Key Takeaways
- • The Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund) announced its first investment, in Emvena Therapeutics, a Philadelphia biotechnology company developing placenta-targeted mRNA medicines.
- • The PxB Fund is a $50 million venture capital fund formed by the University of Pennsylvania, BioNTech SE, and Osage University Partners (OUP), focused on seed and Series A investments in Penn-linked life science companies.
- • Emvena's lead program targets preeclampsia, which affects an estimated 2%–8% of pregnancies worldwide and has no approved therapy addressing the underlying disease.
- • The seed financing will fund Emvena's lead program toward IND-enabling studies and expand its platform into additional maternal and fetal indications; the investment amount was not disclosed.
- • Emvena's technology originates in the Michael J. Mitchell lab at Penn, where a novel lipid nanoparticle delivered mRNA preferentially to the placenta in research published in Nature.
Summary
The Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund) today announced its investment in Emvena Therapeutics, according to a Business Wire release. Emvena is the first company launched and financed by the PxB Fund, which supports the translation of promising University of Pennsylvania research into human health advances.
Emvena is developing mRNA medicines designed to deliver treatments directly to the placenta to address serious maternal and fetal conditions. Its lead program targets preeclampsia, a gestational complication affecting an estimated 2%–8% of pregnancies worldwide. The company notes that preeclampsia has no approved therapy addressing the underlying disease, leaving clinicians largely to manage symptoms and, in severe cases, deliver babies prematurely.
The technology is based on research from the laboratory of Michael J. Mitchell, PhD, the Hibbert Professor of Bioengineering at Penn's School of Engineering and Applied Science. In research published in Nature, the team showed that a novel lipid nanoparticle (LNP) preferentially delivers mRNA to the placenta compared with conventional LNPs. The lab also demonstrated that delivering mRNA encoding vascular endothelial growth factor (VEGF) reduced disease severity in mouse models of preeclampsia. Emvena was founded in 2026.
Anna Turetsky, PhD, General Partner of the PxB Fund, described Emvena as the kind of company the fund intends to catalyze, translating Penn science into potential treatments for a serious unmet medical need. Young T. Kwon, PhD, Emvena's co-founder, Chief Executive Officer and Executive Chair, said the company aims to bring meaningful new treatment options to mothers, babies, and the physicians who care for them. Dr. Mitchell said the PxB Fund moved in a matter of months to launch the company.
Seed proceeds will advance the lead program toward investigational new drug (IND)-enabling studies and expand the placenta-targeted platform into additional maternal and fetal indications. The PxB Fund is managed by Osage University Partners, a Philadelphia-based venture firm with over $800 million under management that has invested in more than 150 startups, including more than 10 from Penn.
Emvena is developing mRNA medicines designed to deliver treatments directly to the placenta to address serious maternal and fetal conditions. Its lead program targets preeclampsia, a gestational complication affecting an estimated 2%–8% of pregnancies worldwide. The company notes that preeclampsia has no approved therapy addressing the underlying disease, leaving clinicians largely to manage symptoms and, in severe cases, deliver babies prematurely.
The technology is based on research from the laboratory of Michael J. Mitchell, PhD, the Hibbert Professor of Bioengineering at Penn's School of Engineering and Applied Science. In research published in Nature, the team showed that a novel lipid nanoparticle (LNP) preferentially delivers mRNA to the placenta compared with conventional LNPs. The lab also demonstrated that delivering mRNA encoding vascular endothelial growth factor (VEGF) reduced disease severity in mouse models of preeclampsia. Emvena was founded in 2026.
Anna Turetsky, PhD, General Partner of the PxB Fund, described Emvena as the kind of company the fund intends to catalyze, translating Penn science into potential treatments for a serious unmet medical need. Young T. Kwon, PhD, Emvena's co-founder, Chief Executive Officer and Executive Chair, said the company aims to bring meaningful new treatment options to mothers, babies, and the physicians who care for them. Dr. Mitchell said the PxB Fund moved in a matter of months to launch the company.
Seed proceeds will advance the lead program toward investigational new drug (IND)-enabling studies and expand the placenta-targeted platform into additional maternal and fetal indications. The PxB Fund is managed by Osage University Partners, a Philadelphia-based venture firm with over $800 million under management that has invested in more than 150 startups, including more than 10 from Penn.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.